Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
Gelteq (NASDAQ: GELS), a company specializing in gel-based delivery solutions for various products including prescription drugs and pet care, has announced its participation in the Benchmark Company 13th Annual Discovery Investor Conference. The event will take place on December 11, 2024, at the New York Athletic Club in New York City.
Co-Founders Nathan Givoni (CEO) and Simon Szewach (Executive Chairman) will be available for one-on-one meetings with analysts and investors throughout the conference day. Interested attendees can arrange meetings through their Benchmark Company representative.
Gelteq (NASDAQ: GELS), un'azienda specializzata in soluzioni di consegna a base di gel per vari prodotti, tra cui farmaci da prescrizione e cura degli animali, ha annunciato la sua partecipazione alla 13a Conferenza Annuale degli Investitori Discovery della Benchmark Company. L'evento si terrà il 11 dicembre 2024, presso il New York Athletic Club a New York City.
I co-fondatori Nathan Givoni (CEO) e Simon Szewach (Presidente Esecutivo) saranno disponibili per incontri individuali con analisti e investitori durante la giornata della conferenza. I partecipanti interessati possono organizzare incontri tramite il loro rappresentante della Benchmark Company.
Gelteq (NASDAQ: GELS), una empresa especializada en soluciones de entrega a base de gel para diversos productos, incluyendo medicamentos recetados y cuidado de mascotas, ha anunciado su participación en la 13.ª Conferencia Anual de Inversores Discovery de Benchmark Company. El evento se llevará a cabo el 11 de diciembre de 2024, en el New York Athletic Club en la ciudad de Nueva York.
Los cofundadores Nathan Givoni (CEO) y Simon Szewach (Presidente Ejecutivo) estarán disponibles para reuniones individuales con analistas e inversores a lo largo del día de la conferencia. Los asistentes interesados pueden coordinar reuniones a través de su representante de Benchmark Company.
겔텍 (NASDAQ: GELS), 처방약 및 반려동물 관리 제품을 포함한 다양한 제품에 대한 젤 기반 전달 솔루션을 전문으로 하는 회사가 벤치마크 컴퍼니 제13회 연례 발견 투자자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 12월 11일에 뉴욕시의 뉴욕 애슬레틱 클럽에서 개최됩니다.
공동 창립자인 네이선 기보니 (CEO)와 사이먼 제바흐 (이사회 의장)는 회의 당일 동안 애널리스트 및 투자자와의 일대일 미팅이 가능합니다. 관심 있는 참석자들은 벤치마크 컴퍼니 담당자를 통해 미팅을 조율할 수 있습니다.
Gelteq (NASDAQ: GELS), une entreprise spécialisée dans des solutions de livraison à base de gel pour divers produits, y compris des médicaments sur ordonnance et des soins pour animaux, a annoncé sa participation à la 13e Conférence Annuelle des Investisseurs Discovery de Benchmark Company. L'événement aura lieu le 11 décembre 2024, au New York Athletic Club à New York City.
Les cofondateurs Nathan Givoni (PDG) et Simon Szewach (Président Exécutif) seront disponibles pour des réunions en tête-à-tête avec des analystes et des investisseurs tout au long de la journée de conférence. Les participants intéressés peuvent organiser des réunions via leur représentant de Benchmark Company.
Gelteq (NASDAQ: GELS), ein Unternehmen, das auf gelbasierte Lieferlösungen für verschiedene Produkte, einschließlich verschreibungspflichtiger Medikamente und Haustierpflege, spezialisiert ist, hat seine Teilnahme an der 13. jährlichen Discovery-Investorenkonferenz der Benchmark Company angekündigt. Die Veranstaltung findet am 11. Dezember 2024 im New York Athletic Club in New York City statt.
Die Mitgründer Nathan Givoni (CEO) und Simon Szewach (Exekutivvorsitzender) stehen während des gesamten Konferenztages für persönliche Meetings mit Analysten und Investoren zur Verfügung. Interessierte Teilnehmer können Meetings über ihren Vertreter der Benchmark Company vereinbaren.
- None.
- None.
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces that its Co-Founders, CEO Mr. Nathan Givoni and Executive Chairman Mr. Simon Szewach, will be participating in the Benchmark Company 13th Annual Discovery Investor Conference being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Mr. Givoni and Mr. Szewach will be hosting one-on-one meetings with analysts and investors throughout the day. To schedule a one-on-one meeting with them, attendees should contact their Benchmark Company representative. Investors can attend the conference by registering here.
About Gelteq Inc.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.
Contact:
CORE IR
516-222-2560
PR@gelteq.com
FAQ
When is Gelteq (GELS) participating in the Benchmark Company Conference?
Who will represent Gelteq (GELS) at the 2024 Benchmark Conference?
What type of meetings will Gelteq (GELS) conduct at the Benchmark Conference 2024?
How can investors meet with Gelteq (GELS) representatives at the Benchmark Conference?
